NVO - Novo Nordisk weight loss drug to undergo EU review for heart conditions
2024-01-22 06:53:49 ET
More on Novo Nordisk
- Taking Novo Nordisk To The Next Level
- Novo Nordisk: Enjoying The Tailwinds Of A Growing Market
- Novo Nordisk A/S (NVO) Presents at J.P. Morgan 42nd Annual Healthcare Conference Transcript
- Lilly, Novo Nordisk diabetes drugs see price raises - report
- Novo Nordisk resumes U.S. shipments of Wegovy 1.7 mg dose
For further details see:
Novo Nordisk weight loss drug to undergo EU review for heart conditions